BERGENBIO TO PRESENT UPDATED CLINICAL DATA AT ASH 2020 MEETING
Bergen, Norway, 30 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce it has been accepted for a poster presentation at the 62[nd] Annual American Society of Hematology (ASH) Meeting, being held virtually from 5-8 December 2020. The poster will provide an update from the Company’s Phase II study of bemcentinib (BGBC003) in combination with low dose cytarabine (LDAC) in elderly relapsed AML patients, and the Phase II BERGAMO trial in patients with